



bioMérieux S.A.
French public limited company (*société anonyme*) with share capital of €12,029,370
Registered office: Marcy l'Étoile (69280), France
Registered with the Lyon Trade and Companies Register under number 673 620 399

ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF MAY 23, 2022

PRELIMINARY NOTICE

The shareholders of bioMérieux (the "Company") are hereby invited to attend the Ordinary and Extraordinary Shareholders' Meeting to be held at 2:00 p.m. (CEST) on May 23, 2022 at 376 Chemin de l'Orme, Marcy l'Etoile (69280), France.

IMPORTANT

In the context of the COVID-19 epidemic, the Company may have to modify the conditions for participating in the Annual General Meeting in the light of legislative and regulatory changes that may occur after the publication of this notice.

Consequently, shareholders are encouraged to regularly consult the Company's website at www.biomerieux.com (Investors > Shareholder Area > General Shareholders' Meeting), which may be updated to specify the definitive conditions for participating in the Annual General Meeting, depending on health and/or legal requirements.

The purpose of the Ordinary and Extraordinary Shareholders' Meeting is to deliberate and decide on the following agenda and draft resolutions:

AGENDA

1. RESOLUTIONS SUBMITTED TO THE ORDINARY GENERAL MEETING

1. Approval of the parent company financial statements for the year ended December 31, 2021; approval of the total amount of expenses and costs referred to in Article 39-4 of the French Tax Code
2. Approval of the consolidated financial statements for the year ended December 31, 2021
3. Granting of discharge to the directors
4. Appropriation of net income for the year ended December 31, 2021
5. Approval of the related-party agreement entered into by the Company with the Fondation Christophe et Rodolphe Mérieux regarding the revision of the sponsorship agreement, as described in the Statutory Auditors' special report
6. Renewal of the term of office of Alexandre Mérieux as a director
7. Renewal of the term of office of Jean-Luc Bélingard as a director
8. Determination of the annual compensation allocated to the members of the Board of Directors
9. Approval of the compensation policy for corporate officers in accordance with Article L.22-10-8 of the French Commercial Code
10. Approval of the compensation policy for the Chairman and Chief Executive Officer in accordance with Article L.22-10-8 of the French Commercial Code
11. Approval of the compensation policy for the Chief Operating Officer in accordance with Article L.22-10-8 of the French Commercial Code
12. Approval of the compensation policy for directors in accordance with Article L.22-10-8 of the French Commercial Code
13. Approval of the components of compensation paid or allocated to corporate officers in respect of the year ended December 31, 2021

14. Approval of the components of compensation paid or allocated to Alexandre Mérieux as Chairman and Chief Executive Officer in respect of the year ended December 31, 2021
15. Approval of the components of compensation paid or allocated to Pierre Boulud as Chief Operating Officer in respect of the year ended December 31, 2021
16. Authorization given to the Board of Directors to enable the Company to buy back its own shares

2. RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING

17. Authorization given to the Board of Directors to reduce the Company's share capital by canceling treasury shares
18. Full powers granted to the bearer of an original copy of the minutes of this Meeting for the purpose of completing formalities

TEXT OF THE DRAFT RESOLUTIONS SUBMITTED BY THE BOARD OF DIRECTORS

1. RESOLUTIONS SUBMITTED TO THE ORDINARY GENERAL MEETING

FIRST RESOLUTION

Approval of the parent company financial statements for the year ended December 31, 2021; approval of the total amount of expenses and costs referred to in Article 39-4 of the French Tax Code

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, and having considered the parent company financial statements for the year ended December 31, 2021, the Board of Directors' management report and the Statutory Auditors' report on the parent company financial statements for the year ended December 31, 2021, the shareholders approve the parent company financial statements for the year ended December 31, 2021 as submitted to them, showing net income of €205,625,092.05. They also approve the transactions reflected in those financial statements or summarized in those reports.

In accordance with Article 223 *quater* of the French Tax Code (*Code général des impôts*), the shareholders approve the total amount of non-deductible costs and expenses referred to in Article 39-4 of said Code, which amounted to €655,923 for the year ended December 31, 2021, as well as the amount of tax paid by the Company in light of their non-deductible nature, i.e., €180,379. In addition, the shareholders take note of the detailed list of the expense categories referred to in paragraph 5 of Article 39 of the French Tax Code and presented in accordance with Article 223 *quinquies* of said Code.

SECOND RESOLUTION

Approval of the consolidated financial statements for the year ended December 31, 2021

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, and having considered the Board of Directors' report on the management of the Group and the Statutory Auditors' report on the consolidated financial statements for the year ended December 31, 2021, which show consolidated net income of €598,190,433, the shareholders approve the consolidated financial statements for the year ended December 31, 2021 as submitted to them, as well as the transactions reflected in those financial statements or summarized in the Group management report.

THIRD RESOLUTION

Granting of discharge to the directors

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings and having considered (i) the Board of Directors' management report, (ii) the corporate governance report, and (iii) the Statutory Auditors' report thereon, the shareholders take note of the content of those reports and grant discharge to the directors for their duties during the previous financial year.

FOURTH RESOLUTION

Appropriation of net income for the year ended December 31, 2021

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings and subsequent to the adoption of the first resolution, the shareholders note that (i) the statutory reserve exceeds 10% of the share capital and that (ii) the balance sheet for the year ended December 31, 2021 shows net income of €205,625,092.05 which, when increased by retained earnings of €58,336,420.17 results in distributable net income of €263,961,512.22.

The shareholders therefore resolve, on a proposal by the Board of Directors, to appropriate said distributable net income as follows:

- €10,000,000.00 to be transferred to the "General reserve", increasing the balance from €865,000,000.28 to €875,000,000.28;
- €26,960.00 to be transferred to the "Special sponsorship reserve", increasing the balance from €993,092.58 to €1,020,052.58;
- €100,607,037.00 to be distributed as dividends;
- the remaining €153,327,515.22 to be transferred to "Retained earnings".

Each shareholder would thereby receive a dividend of €0.85 per share.

This dividend would be paid at the latest on June 8, 2022.

In accordance with the provisions of Article L.225-210 of the French Commercial Code (*Code de Commerce*), the Company will not receive any dividends on treasury shares held on the ex-dividend date. The corresponding dividend amount will be allocated to "Retained earnings".

The shareholders take note that the sums distributed as dividends over the past three financial years, were as follows:

Year ended	Distributed dividends (in euros) ^(*)	Distributed dividends per share (in euros)
Dec. 31, 2020	73,383,956.40	0.62
Dec. 31, 2019	22,488,631.80	0.19
Dec. 31, 2018	41,426,427.00	0.35

(*) The Company did not receive any dividends on treasury shares held on the ex-dividend date. The corresponding dividend amount was allocated to "Retained earnings".

Under current French tax legislation, the dividends distributed to individuals domiciled in France for tax purposes are taxed in two phases:

- In the payment year, the gross amount of dividends received is subject to a mandatory, non-discharging flat-rate (PFNL) income tax installment of 12.8% in application of Article 117 *quarter* of the French Tax Code, and social security withholdings of 17.2%. Low-income taxpayers may request an exemption from the PNFL levy, subject to certain conditions.
- The following year, they are subject to income tax at the flat rate of 12.8% (withholding tax – PFU), or optionally, according to the progressive income tax scale. In the latter case, a 40% allowance (Article 158, 3²° of the French Tax Code) is applied to the gross amount received.

The PFNL of 12.8%, withheld during the payment year, is deducted from the income tax due in the following year. The excess is refunded, if applicable.

FIFTH RESOLUTION

Approval of the related-party agreement entered into by the Company with the Fondation Christophe et Rodolphe Mérieux regarding the revision of the sponsorship agreement as described in the Statutory Auditors' special report

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, and having considered the Statutory Auditors' special report, presented in accordance with the provisions of Article L.225-40 of the French Commercial Code, on the agreements referred to in Articles L.225-38 *et seq.* of said Code, the shareholders approve the agreement entered into with the Fondation Christophe et Rodolphe Mérieux under the terms and conditions described in the Statutory Auditors' report, as well as the Statutory Auditors' conclusions on said agreement as set out in the report.

SIXTH RESOLUTION

*Renewal of the term of office of Alexandre Mérieux
as a director*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, on a proposal by the Board of Directors, the shareholders resolve to renew the term of office of Alexandre Mérieux as a director, for a further period of four years, i.e., until the Annual General Meeting called to approve the financial statements for the year ending December 31, 2025.

SEVENTH RESOLUTION

*Renewal of the term of office of Jean-Luc Bélingard
as a director*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, on a proposal by the Board of Directors, the shareholders resolve to renew the term of office of Jean-Luc Bélingard as a director, for a further period of four years, i.e., until the Annual General Meeting called to approve the financial statements for the year ending December 31, 2025.

EIGHTH RESOLUTION

Determination of the annual compensation allocated to the members of the Board of Directors

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, on a proposal by the Board of Directors, the shareholders resolve to set the total annual compensation allocated to the directors at €500,000 (five hundred thousand euros) for the current financial year and for subsequent financial years, until further decision by the Annual General Meeting.

NINTH RESOLUTION

*Approval of the compensation policy for corporate officers
in accordance with Article L.22-10-8 of the French Commercial Code*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-8 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, the shareholders approve the compensation policy for corporate officers, as presented in Chapter 4.3.1 of the 2021 Universal Registration Document, which includes said corporate governance report.

TENTH RESOLUTION

*Approval of the compensation policy for the Chairman and Chief Executive Officer
in accordance with Article L.22-10-8 of the French Commercial Code*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-8 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, the shareholders approve the compensation policy for the Chairman and Chief Executive Officer, as presented in Chapter 4.3.1 of the 2021 Universal Registration Document, which includes said corporate governance report.

ELEVENTH RESOLUTION

*Approval of the compensation policy for the Chief Operating Officer
in accordance with Article L.22-10-8 of the French Commercial Code*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-8 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L. 225-37 of the French Commercial Code, the shareholders approve the compensation policy for the Chief Operating Officer, as presented in Chapter 4.3.1 of the 2021 Universal Registration Document, which includes said corporate governance report.

TWELFTH RESOLUTION

*Approval of the compensation policy for directors
in accordance with Article L.22-10-8 of the French Commercial Code*

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-8 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, the shareholders approve the compensation policy for directors, as presented in Chapter 4.3.1 of the 2021 Universal Registration Document, which includes said corporate governance report.

THIRTEENTH RESOLUTION

Approval of the components of compensation paid or allocated to corporate officers in respect of the year ended December 31, 2021

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-34 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, including the report on the compensation of the Company's corporate officers, the shareholders approve said report, as presented in Chapter 4.3.2 of the 2021 Universal Registration Document, which includes said corporate governance report.

FOURTEENTH RESOLUTION

Approval of the components of compensation paid or allocated to Alexandre Mérieux as Chairman and Chief Executive Officer in respect of the year ended December 31, 2021

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-34 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, the shareholders approve the fixed, variable and exceptional components of the total compensation and benefits in kind paid or allocated for the year ended December 31, 2021 to Alexandre Mérieux in respect of his office as Chairman and Chief Executive Officer, as indicated in Chapter 4.3.2 of the 2021 Universal Registration Document, which includes said corporate governance report.

FIFTEENTH RESOLUTION

Approval of the components of compensation paid or allocated to Pierre Boulud as Chief Operating Officer in respect of the year ended December 31, 2021

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, in application of Article L.22-10-34 of the French Commercial Code, and having considered the Board of Directors' corporate governance report prepared in application of Article L.225-37 of the French Commercial Code, the shareholders approve the fixed, variable and exceptional components of the total compensation and benefits in kind paid or allocated for the year ended December 31, 2021 to Pierre Boulud in respect of his office as Chief Operating Officer, as indicated in Chapter 4.3.2 of the 2021 Universal Registration Document, which includes said corporate governance report.

SIXTEENTH RESOLUTION

Authorization given to the Board of Directors to enable the Company to buy back its own shares

Voting in accordance with the quorum and majority rules applicable to ordinary shareholders' meetings, and having considered the Board of Directors' report, in accordance with Article L.22-10-62 of the French Commercial Code, the shareholders authorize the Board of Directors, which may delegate its powers, to purchase, on the Company's behalf, on one or more occasions, whenever it deems appropriate, a number of the Company's own shares, within the legal limit of 10% of its share capital (with said limit applying at any time whatsoever to the share capital as adjusted in light of capital transactions carried out subsequent to this Meeting), it being specified that the maximum number of shares bought back by the Company for the purpose of being held in treasury for subsequent delivery in exchange for a merger, spin-off or contribution is capped at 5% of the share capital, as provided by law.

This authorization is given to enable the Company, in descending order of priority, to:

- maintain a liquid secondary market for bioMérieux's shares through market-making transactions carried out by an independent investment services provider under a liquidity agreement that complies with the regulations of the French financial markets authority (*Autorité des marchés financiers* – AMF);
- deliver shares under stock option plans and/or free share plans (or similar plans) to employees and/or corporate officers of the Group, allocate shares under a Company or Group employee savings plan (or similar plan) in connection with Company profit-sharing and/or allocate shares under any other share allocations to employees and/or corporate officers of the Group;
- reduce the Company's share capital by canceling shares within the legal limits;
- hold shares for their subsequent delivery in payment or exchange for external growth transactions;
- implement any market practices permitted or that may be permitted by the market authorities.

Under this authorization, the Company may buy back its own shares within the limits set out below (which may be adjusted in connection with transactions affecting the Company's share capital).

The maximum purchase price per share may not exceed €250 excluding acquisition-related fees.

The maximum theoretical amount set aside for this program is €2,959,030,500 (maximum theoretical amount excluding treasury shares). However, the Board of Directors, which may delegate its powers in accordance with the law, may adjust the aforementioned purchase price in the event of a change in the par value of the shares, a capital increase through the capitalization of reserves and the granting of free shares, stock splits or reverse splits, capital redemptions or reductions, the distribution of reserves or other assets and any other transactions affecting equity, in order to take into account the impact of such transactions on the value of the shares.

The shareholders resolve that the shares may be purchased, sold or transferred by any means, including through the use of derivative financial instruments, both on the stock market or over the counter, excluding the sale of put options, except in the case of exchanges in accordance with applicable regulations. No restriction applies to the portion of shares bought back through block trades, which may account for the entire program.

Shares held for purposes that are no longer compatible with the Company's strategy may be sold subject to the approval of the Board of Directors and provided that the financial markets are informed thereof.

Consequently, full powers are granted to the Board of Directors – which may delegate those powers to the Chief Executive Officer or, with the approval of the latter, to one or more Chief Operating Officers – to place any and all trading orders, enter into any and all agreements, make any and all filings with the AMF and any other organization, carry out all other formalities, and generally do everything necessary to use this authorization. The persons thus designated will report to the Board of Directors on how this authorization is used.

With effect from the date hereof, this authorization supersedes the unused portion of any authorizations previously given for the same purpose, and is given for a period expiring at the close of the Annual General Meeting to be called to approve the financial statements for the year ending December 31, 2022 or for a period of 18 months from this Annual General Meeting, whichever is the earlier. It may be used at any time, except during a public purchase and/or exchange offer initiated by the Company, subject to applicable laws and regulations.

The Board of Directors will report to the Annual General Meeting on the transactions carried out pursuant to this authorization.

2. RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING

SEVENTEENTH RESOLUTION

Authorization given to the Board of Directors to reduce the Company's share capital by canceling treasury shares

Voting in accordance with the quorum and majority rules applicable to extraordinary shareholders' meetings, and having considered the Board of Directors' report and the Statutory Auditors' special report, subject to the adoption of the sixteenth resolution of this Meeting, the shareholders authorize the Board of Directors, pursuant to Article L.22-10-62 of the French Commercial Code, to reduce the Company's share capital by canceling all or some of the shares bought back by the Company pursuant to the share buyback program authorized pursuant to the sixteenth resolution of this Meeting, at its sole discretion, on one or more occasions, within the limit of 10% of the share capital over a period of 24 months from the date of this Meeting, and reducing the share capital by the same amount. The abovementioned limit of 10% applies to the amount of the Company's share capital, which may be adjusted to reflect capital transactions carried out subsequent to this Meeting.

The shareholders authorize the Board of Directors to offset any excess of the purchase price of canceled shares over their par value against existing paid-in capital or available reserve accounts, and grant full powers to the Board of Directors, which may be delegated under the conditions set by law, for the purpose of carrying out any and all formalities and making any and all filings necessary to finalize the capital reductions under this authorization, and to amend the bylaws accordingly.

This authorization is given to the Board of Directors for a period of 18 months from the date of this Meeting. With effect from the date hereof, it supersedes any other prior authorization for the same purpose.

EIGHTEENTH RESOLUTION

Full powers granted to the bearer of an original copy of the minutes of this Meeting for the purpose of completing formalities

Voting in accordance with the quorum and majority rules applicable to extraordinary shareholders' meetings, the shareholders grant full powers to the bearer of an original copy of the minutes of this Annual General Meeting, or of a copy or extract thereof, for the purpose of completing all necessary formalities.

1. CONDITIONS FOR PARTICIPATING IN THE ANNUAL GENERAL MEETING

All shareholders have the right to attend the Annual General Meeting, irrespective of the number of shares they hold.

In accordance with Article R.22-10-28 of the French Commercial Code (*Code de Commerce*), shareholders must provide proof of ownership of their shares by the second business day preceding the Annual General Meeting, i.e., 00:00 a.m. (CEST) on the morning of May 19, 2022, either in the registered share accounts kept on the Company's behalf by its authorized agent, BNP PARIBAS Securities Services, or in the bearer share accounts held by an authorized intermediary.

Shareholders may participate in the Annual General Meeting:

- (i) by attending in person;
- (ii) by voting by post;
- (iii) by giving a proxy to the Chairman of the Meeting, to their spouse or the partner with whom they have entered into a civil union, to another shareholder, to any other individual or legal entity of their choice under the conditions provided for in Article L.22-10-39 of the French Commercial Code, or without indicating a proxy; it is specified that for any proxy given by a shareholder without indicating a proxy, the Chairman of the Meeting will vote to adopt the proposed resolutions presented or supported by the Board of Directors and vote against all other proposed resolutions; or
- (iv) by voting on the Internet via the VOTACCESS secure platform.

In accordance with the provisions of Article R.22-10-28 of the French Commercial Code, any shareholder who has already cast a postal vote, sent a proxy form or requested an admittance card or a share ownership certificate to attend the Annual General Meeting may no longer choose another means of participating in the Annual General Meeting. However, they may sell all or some of their shares.

1. Shareholders wishing to attend the Annual General Meeting in person may request an admittance card by post or online:

For holders of registered shares:

- either contact BNP PARIBAS Securities Services – CTO Assemblées Générales – Grands Moulins de Pantin – 9 rue du Débarcadère – 93761 Pantin Cedex, France;
- or apply online on the secure VOTACCESS platform accessible via the Planetshares website at the following address: <https://planetshares.bnpparibas.com>.

Holders of pure registered shares should log on to the Planetshares website using their usual access codes. Holders of shares registered in administered registered form should log on to the Planetshares website using their identifier number, which can be found in the top right-hand corner of the paper voting form. Shareholders who have forgotten their login and/or password may call 0 826 109 119 from France or +33 1 55 77 40 57 from abroad.

After logging on, registered shareholders should follow the instructions on the screen to access the VOTACCESS site and request an admittance card;

- or, on the day of the Meeting, go directly to the counter specially provided for this purpose with an identity document.

For holders of bearer shares:

- either ask the intermediary who manages your shares to send you an admittance card;
- or, if the authorized intermediary who manages your account is connected to the VOTACCESS website, request an admittance card electronically as follows: after logging on to the intermediary's Internet portal with your usual access codes, click on the icon appearing on the line corresponding to your bioMérieux shares and follow the instructions on the screen to access the VOTACCESS site and request an admittance card.

2. Shareholders not attending the Annual General Meeting in person and who wish to vote by post or by proxy under the legal and regulatory conditions, in particular those provided for in Articles L.225-106 and L.22-10-39 of the French Commercial Code, may:

For holders of registered shares: return the single postal voting form or proxy form, which will be sent with the notice of meeting, unless you have requested to receive the notice by electronic means, to the following address: BNP PARIBAS Securities Services – CTO Assemblées Générales – Grands Moulins de Pantin – 9 rue du Débarcadère – 93761 Pantin Cedex, France.

For holders of bearer shares: request the single postal voting form or proxy form from the intermediary who manages your shares as of the date the Annual General Meeting is convened; this single form must be accompanied by a share ownership certificate issued by the financial intermediary and sent to: BNP PARIBAS Securities Services – CTO Assemblées Générales – Grands Moulins de Pantin – 9 rue du Débarcadère – 93761 Pantin Cedex, France.

To be taken into account, the voting form and the share ownership certificate must be received by bioMérieux or BNP PARIBAS Securities Services no later than three calendar days preceding the date of the Annual General Meeting, i.e., 11:59 p.m. (CEST) on May 19, 2022.

3. Shareholders will be able to vote online via the secure VOTACCESS website, which will be open from May 2, 2022 to May 22, 2022 at 3:00 p.m. (CEST).

For holders of registered shares:

- log on to VOTACCESS via the Planetshares website: <https://planetshares.bnpparibas.com>;
- holders of pure registered shares should log on to the Planetshares website using their usual access codes. Holders of administered registered shares should log on to the Planetshares website using their login number, which can be found in the top right-hand corner of the printed voting form. Shareholders who have forgotten their login and/or password may call 0 826 109 119 from France or +33 1 55 77 40 57 from abroad.

After logging on, shareholders must follow the instructions on the screen to access the VOTACCESS site and vote.

For holders of bearer shares:

- log on to the portal of the company that holds your account with your usual access codes and click on the icon appearing on the line corresponding to your bioMérieux shares to access the VOTACCESS site;
- follow the procedure indicated on the screen. Only holders of bearer shares whose account-holding institution has joined the VOTACCESS website may vote online. If the holder of your securities account has not joined VOTACCESS or subjects access to the site to conditions of use, it must tell shareholders how to proceed.

Shareholders are advised not to wait until the last few days to vote, in order to avoid possible congestion in Internet communications.

2. NOTIFICATION OF THE APPOINTMENT OR REVOCATION OF A PROXY

To be valid, appointments or revocations of proxies other than the Chairman of the Meeting must be received no later than the third day preceding the date of the Meeting when submitted by post, i.e., May 20, 2022, or no later than the day before the Meeting when submitted electronically, i.e., 3:00 p.m. (CEST) on May 22, 2022, in one of the following ways:

- either via VOTACCESS, as described above;
- or by post to the following address: BNP PARIBAS Securities Services – CTO Assemblées Générales – Grands Moulins de Pantin – 9 rue du Débarcadère – 93761 Pantin Cedex, France.
- or by email to: paris.bp2s.france.cts.mandats@bnpparibas.com. This email must contain the following information: the name of the company concerned (bioMérieux), the date of the meeting (May 23, 2022), your last name, first name, address and bank details, and the last name, first name and, if possible, address of the proxy you wish to appoint. If you are a bearer shareholder, you must ask the financial intermediary who manages your securities account to send written confirmation to the following address: BNP PARIBAS Securities Services – CTO Assemblées Générales – Grands Moulins de Pantin – 9 rue du Débarcadère – 93761 Pantin Cedex, France.

Only notice of the appointment or revocation of proxies may be sent to this email address; requests or notices relating to any other matters will not be processed and/or taken into account.

3. REQUEST FOR THE INCLUSION OF DRAFT RESOLUTIONS OR ITEMS ON THE AGENDA

One or more shareholders representing at least the fraction of the capital provided for by the applicable legal and regulatory provisions may request the inclusion of items on the agenda or draft resolutions under the conditions provided for in Articles L.225-105 and R.225-71 to R.225-73 and R.22-10-22 of the French Commercial Code.

In accordance with the conditions set out in Article R.225-73 of the French Commercial Code, requests for the inclusion of items or draft resolutions on the agenda by shareholders meeting the legal requirements must reach the Company's registered office by registered letter with acknowledgment of receipt no later than the twenty-fifth calendar day preceding the date of the Annual General Meeting, i.e., April 27, 2022.

They must be accompanied by a certificate of account registration proving that the authors of the request hold or represent the fraction of the capital required by the aforementioned Article R.225-71. The request for the inclusion of draft resolutions must also

be accompanied by the text of the draft resolutions, and the request for the inclusion of items on the agenda must be accompanied by a short explanatory statement.

Items or draft resolutions submitted by shareholders in accordance with the law will be reviewed at the Annual General Meeting provided such shareholders have submitted a new certificate proving registration of their shares in the account under the same conditions no later than the second business day preceding the date of the Annual General Meeting.

These new items or draft resolutions will be placed on the agenda of the Meeting and brought to the attention of the shareholders under the conditions determined by the regulations in force.

4. WRITTEN QUESTIONS

In accordance with Article R.225-84 of the French Commercial Code, all shareholders may submit questions in writing to the Chairman of the Board of Directors upon receipt of this notice. Any questions must be sent to the Chairman of the Board of Directors at the following email address investor.relations@biomerieux.com, no later than the fourth business day preceding the date of the Annual General Meeting, i.e., May 17, 2022, accompanied by a share ownership certificate.

All written questions and answers will be published on the Company's website at www.biomerieux.com (Investors > Shareholder Area > General Shareholders' Meeting) within the time limits imposed by the regulations.

5. SHAREHOLDERS' RIGHT OF COMMUNICATION

Shareholders may obtain the documents referred to in Articles R.225-81 and R.225-83 of the French Commercial Code by sending a simple request by email to investor.relations@biomerieux.com or to BNP Paribas Securities Services.

The documents that must be made available to the shareholders in connection with the Meeting will be made available at the Company's registered office within the legal time limits.

The documents and information referred to in Article R.22-10-23 of the French Commercial Code that are to be presented at the Meeting will be made available on the Company's website at www.biomerieux.com (Investors > Shareholder Area > General Shareholders' Meeting), no later than from the twenty-first day preceding the date of the Annual General Meeting, i.e., May 2, 2022.

This preliminary notice of meeting will be followed by a convening notice containing any changes made to the agenda following requests to include draft resolutions submitted by the shareholders or the Social and Economic Committee.